Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kaled Diab

Vascular Surgery The Woodlands, TX Medical Doctor

NPI 1861998692 CMS profile 11453130

17189 Interstate 45 S, Suite 475, The Woodlands, TX 77385

Open in the dashboard

General payments

$6,512

108 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kaled Diab of The Woodlands, TX is reported in the CMS Open Payments database as having received $6,512 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $721 21
2024 General $2,052 44
2023 General $3,693 40
2021 General $45 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kaled Diab
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Kaled Diab were reported at $721. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Kaled Diab Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $0 $348 $118–$1,110 $114
2021 $45 $471 $158–$1,421 $132
2022 $0 $725 $222–$2,183 $149
2023 $3,693 $836 $257–$2,440 $160
2024 $2,052 $909 $252–$2,619 $164
2025 $721 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. W. L. Gore & Associates, Inc. $2,686 25 payments
  2. Silk Road Medical, Inc. $423 5 payments
  3. Merit Medical Systems Inc $350 1 payment
  4. Inari Medical, Inc. $328 2 payments
  5. Boston Scientific Corporation $319 12 payments
  6. Surmodics, Inc. $296 10 payments
  7. Baxter Healthcare $261 4 payments
  8. TissueTech, Inc. $257 6 payments
  9. Medtronic, Inc. $179 4 payments
  10. Atricure, Inc. $172 4 payments
  11. Other $1,240 35 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,274 103 payments
  2. Travel and Lodging $1,888 4 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $350 1 payment
Products named General payments · program years 2021–2025
  1. GORE VIABAHN Endoprosthesis with Heparin $703 1 payment
  2. VIABAHN Endoprosthesis with PROPATEN Bioactive Surface $633 2 payments
  3. GORE ACUSEAL Vascular Graft $559 2 payments
  4. GORE VIABAHN VBX Balloon Expandable Endo $499 8 payments
  5. ENROUTE Transcarotid Stent $423 5 payments
  6. ENROUTE Transcarotid Neuroprotection System $423 5 payments
  7. HeRO Graft $350 1 payment
  8. Surfacer Inside-Out Catheter $350 1 payment
  9. CT THROMBECTOMY SYSTEM KIT $328 2 payments
  10. FLOWTRIEVER CATHETER, S $328 2 payments
  11. Other $4,317 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

41

Median for Vascular Surgery: 122

Drug cost

$14,917

Median for Vascular Surgery: $14,135

Branded share of claims

61%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 14 $14,656
Doxycycline Hyclate Generic 16 $204
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$107,413

Medicare's payments for the services billed

Medicare patients

208

Average age 74

Services billed

797

95 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Chronic kidney disease 59%
Ischemic heart disease 58%
Diabetes 53%
Heart failure 47%
Depression 35%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVKEEZA
  • Regeneron Healthcare Solutions, Inc. $37
$37 — —
VYNDAQEL
  • PFIZER INC. $19
$19 — —
Repatha
  • Amgen Inc. $14
$14 — —
RYBELSUS
  • Novo Nordisk Inc $9
$9 — —
Ozempic
  • Novo Nordisk Inc $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record